Complete loss of SMARCB1/SNF5 is very common in malignant rhabdoid tumors (MRT) and atypical teratoid/rhabdoid tumors (ATRT) [12–15]. Here, SMARCB1 is linked to atypical teratoid rhabdoid tumor.